Center for Digestive Endoscopy, Saint-Antoine Hospital
Paris, France
Location status: Recruiting
NCT Number: NCT07472686
The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown.
The iCARE4Lynch study is a retrospective cohort of patients carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM) who had had at least one SBCE for screening of small bowel (pre)neoplastic lesions between January 1st 2000 and December 31 2024.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Paris, France
Location status: Recruiting
Population study
Participating investigators
Members of the international CApsule endoscopy REsearch (iCARE) group
Objectives The primary objective of the study is to estimate the diagnostic performance of a first (index) SB CE for screening of small bowel (pre)neoplastic lesions in patients with LS.
Secondary objectives are to estimate, in this setting:
Origin of personal health data (source(s) used) This research focuses on the analysis of data collected as part of the routine clinical care of patients (no additional examination will be requested). Data will be collected from patient medical records (paper and digital).
Personal data circuit and method for protecting the confidentiality of personal data The personal data circuit concerns the use of care data from capsule endoscopy (CE) examination reports in paper files or stored in the Orbis software present in the APHP computer network or the CE software of each associated hospital center.
A correspondence table with order numbers will be used. There will be no circulation or exchange of data. Access to the data is secured at the APHP network and the data will be archived for 15 years in the coordinating center.
Information concerning deceased persons, including that which appears on death certificates, may be processed for research, study or health evaluation purposes, unless the patient has, during his or her lifetime, expressed his or her written refusal.
The vital status of patients will be investigated before data collection (alive or deceased).
Variables and analysis Patient data: Age at SBCE; Gender; Pathogenic variant of MMR gene; History of LS-related cancer; History and type of digestive surgery; First-degree family history (parents, siblings, children) of small bowel adenocarcinoma;
Indication for SBCE: screening, family history, clinical or radiological diagnosis;
Timing and organization of the study, research or evaluation:
Data collected from January 1st 2000 to December 31st 2024. Total study duration: 12 months
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At the end of the study (12 month)
Diagnostic performance of index SBCE
Time frame: At the end of the study (12 month)
Time frame: At the end of the study (12 month)
completeness rate is the entire small bowel visualized, depending on past surgical history
Time frame: 12 months
Time frame: 12 months
Time frame: At the end of the study (12 month)
Proportion of patients in whom at least one small bowel pre-neoplastic (low or high grade adenoma) or neoplastic (adenocarcinoma) lesion, secondarily proven during follow-up, was identified on a follow up SBCE, compared to the total number of patients with follow-up SBCE in this setting.
Time frame: At the end of the study (12 month)
Age at diagnosis of small bowel (pre)neoplastic lesions in patients with LS, monitored by repeat SBCE;
Time frame: At the end of the study (12 month)
Diagnostic performance according to genetic variants
Time frame: At the end of the study (12 month)
Type of treatment: endoscopic, surgical, pharmacological, abstention or other.
Time frame: At the end of the study (12 month)
Post-therapeutic follow-up of any lesion of (pre)neoplastic appearance of the small bowel detected on a SBCE: anatomopathological analysis of any lesion of (pre)neoplastic appearance of the small bowel detected by SBCE, and consequences (cure, recurrence, additional treatments, death).
Contact information is provided by the study sponsor or research team.
Aymeric BECQ, MD
CONTACT
Xavier DRAY, MD PhD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Small Bowel Capsule Endoscopy for (Pre)Neoplastic Lesion Screening in Patients With Lynch Syndrome
Acronym: iCARE4Lynch
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05129605
ATM Gene Mutation, BRCA1 Mutation
Boston, Massachusetts, United States
View Trial DetailsNCT03702309
Adnexal Diseases, BRCA1 Mutation
Toronto, Ontario, Canada
View Trial DetailsNCT03303833
Colonic Diseases, Colorectal Neoplasms
Wageningen, Netherlands
View Trial DetailsNCT05754801
Cancer, Neoplasms
Hong Kong
View Trial Details